These findings collectively demonstrated that targeting CDC7 with Olaparib trigger anti‐tumor immunity through activating cGAS/STING signaling pathway and boosts T cell activation, suggesting its potential as an effective therapeutic strategy. This evidence concerns the gene CDC7 and neoplasm.